Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up

Hepatology

Volumn 50, Issue 4, 2009, Pages 1030-1037

  Corey, Kathleen E ^a,b   Kane, Erin ^b   Munroe, Craig ^a   Barlow, Lydia L ^a   Zheng, Hui ^a,b   Chung, Raymond T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIVIRUS AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERFERON; LIPID; LOW DENSITY LIPOPROTEIN; PEGINTERFERON; RIBAVIRIN; TRIACYLGLYCEROL; ALPHA2A INTERFERON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; VIRUS RNA;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET RESTRICTION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERLIPIDEMIA; HYPOLIPEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; BLOOD; CROSS-SECTIONAL STUDY; DRUG EFFECT; GENETICS; LIPID METABOLISM; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, LDL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 70350044610     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23219     Document Type: Article

References (24)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitisCvirus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
2. Diaz O, Delers F, Maynard M, Demignot S, Zoulim F, Chambaz J, et al. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 2006;87:2983-2991.
3. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002;76:6919-6928.
4. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999;96:12766-12771.
5. Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007;46: 411-419.
6. Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol 2002;12: 517-523.
7. Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003;100:15865-15870.
8. Wang C, GaleMJr, Keller BC, Huang H, Brown MS, Goldstein JL, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005;18:425-434.
9. Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. HEPATOLOGY 2008;47:1437-1445.
10. Maggi G, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia C, et al. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 1996;28: 436-440.
11. Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007;56:1105-1110.
12. Munroe C, Chan J, Zheng, H, Chung RT. Incidence of hyperlipidemia in chronic hepatitis C and response to anti-viral therapy in combination with HMG-CoA reductase inhibitors [Abstract M1779]. Presented at: Digestive Disease Week 2007; May 19-24; Washington, DC.
13. National Heart, Lung and Blood Institute. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Bethesda, MD: National Institutes of Health; 2004.
14. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-2828.
15. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997;261:159-165.
16. Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS 2007;21:479-491.
17. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. HEPATOLOGY 2006;44:335-340.
18. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997;157:792-796.
19. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
20. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
21. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
22. Seyam MS, Freshwater DA, O'Donnell K, Mutimer DJ. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. J Viral Hepat 2005;12:531-535.
23. Soardo G, Pirisi M, Fonda M, Fabris C, Falleti E, Toniutto P, et al. Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C. J Interferon Cytokine Res 1995;15:705-712.
24. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.